Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein

BACKGROUND: Patients with antibody deficiency respond poorly to coronavirus disease 2019 (COVID-19) vaccination and are at risk of severe or prolonged infection. They are given long-term immunoglobulin replacement therapy (IRT) prepared from healthy donor plasma to confer passive immunity against in...

Descripción completa

Detalles Bibliográficos
Autores principales: Upasani, Vinit, Townsend, Katie, Wu, Mary Y, Carr, Edward J, Hobbs, Agnieszka, Dowgier, Giulia, Ragno, Martina, Herman, Lou S, Sharma, Sonal, Shah, Devesh, Lee, Simon F K, Chauhan, Neil, Glanville, Julie M, Neave, Lucy, Hanson, Steven, Ravichandran, Sriram, Tynan, Aoife, O’Sullivan, Mary, Moreira, Fernando, Workman, Sarita, Symes, Andrew, Burns, Siobhan O, Tadros, Susan, Hart, Jennifer C L, Beale, Rupert C L, Gandhi, Sonia, Wall, Emma C, McCoy, Laura, Lowe, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552578/
https://www.ncbi.nlm.nih.gov/pubmed/37338118
http://dx.doi.org/10.1093/cid/ciad368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552578/
https://www.ncbi.nlm.nih.gov/pubmed/37338118
http://dx.doi.org/10.1093/cid/ciad368

Ejemplares similares